Exciting News: Novartis and Avidity Biosciences Engage in Groundbreaking Talks for Revolutionary Therapies!
Swiss pharmaceutical powerhouse Novartis AG is reportedly approaching a significant acquisition, eyeing biotechnology firm Avidity Biosciences at a price exceeding $70 per share, according to Bloomberg News sources. An official announcement regarding the deal could be imminent, with expectations of a reveal as soon as this Sunday.
Neither Novartis nor Avidity offered immediate responses to requests for comments from CNBC, leaving the details of the potential transaction largely speculative for now. Avidity is recognized for its cutting-edge development of ribonucleic acid (RNA) therapeutics known as antibody oligonucleotide conjugates. This emerging category of RNA-based treatments aims to modify gene expression to combat various diseases, marking a progressive shift in therapeutic approaches.
This acquisition talks align with Novartis’s broader strategy to bolster its research and development capabilities. Earlier this year, the company revealed intentions to invest a substantial $23 billion to enhance its U.S. infrastructure, which includes plans for a new R&D hub in San Diego. Additionally, Novartis has strengthened its position in the pharmaceutical landscape through recent agreements with Anthos Therapeutics and Regulus Therapeutics, aimed at advancing the development of drugs targeting cardiovascular and kidney illnesses.
As of last Friday, Avidity’s shares closed at $49.15, reflecting a robust market performance with an approximate 70% increase year-to-date, pushing its market capitalization to around $7.2 billion. In contrast, Novartis’s stock ended the trading day at $130.36.
As developments unfold, the merger could significantly enhance Novartis’s portfolio and solidify its commitment to innovative therapeutic solutions. The interest in Avidity underscores the growing significance of RNA-based treatments within the pharmaceutical landscape, setting the stage for potential breakthroughs in disease management.
For a comprehensive view of the ongoing developments, follow Bloomberg News for updates regarding this evolving story.
Categories: Pharma News, Biotechnology, Business Expansion, Corporate Acquisitions
Tags: Novartis, Avidity Biosciences, RNA Therapeutics, Pharmaceutical Investments, Biotechnology Acquisition
Original Source: https://www.cnbc.com/2025/10/26/novartis-avidity-biosciences-talks.html
Category :
Tags:
Publish Date: 2025-10-26 21:56:00
